X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8279) 8279
Book Review (1257) 1257
Publication (515) 515
Newsletter (473) 473
Conference Proceeding (91) 91
Newspaper Article (27) 27
Book Chapter (21) 21
Dissertation (9) 9
Magazine Article (9) 9
Trade Publication Article (6) 6
Web Resource (3) 3
Transcript (2) 2
Paper (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
capecitabine (7411) 7411
index medicus (5887) 5887
humans (5850) 5850
oncology (4731) 4731
female (4140) 4140
deoxycytidine - analogs & derivatives (3359) 3359
middle aged (3325) 3325
chemotherapy (3241) 3241
aged (3178) 3178
fluorouracil - analogs & derivatives (2989) 2989
male (2856) 2856
antineoplastic combined chemotherapy protocols - therapeutic use (2720) 2720
cancer (2626) 2626
adult (2533) 2533
deoxycytidine - administration & dosage (2258) 2258
fluorouracil - administration & dosage (2191) 2191
treatment outcome (1918) 1918
care and treatment (1535) 1535
oxaliplatin (1405) 1405
breast neoplasms - drug therapy (1357) 1357
colorectal cancer (1325) 1325
fluorouracil (1317) 1317
breast cancer (1282) 1282
5-fluorouracil (1268) 1268
antineoplastic combined chemotherapy protocols - adverse effects (1265) 1265
metastasis (1230) 1230
research (1205) 1205
therapy (1160) 1160
deoxycytidine - adverse effects (1132) 1132
aged, 80 and over (1113) 1113
deoxycytidine - therapeutic use (1099) 1099
colorectal neoplasms - drug therapy (1056) 1056
disease-free survival (1036) 1036
fluorouracil - adverse effects (1028) 1028
fluorouracil - therapeutic use (957) 957
trial (929) 929
organoplatinum compounds - administration & dosage (927) 927
neoplasm staging (926) 926
pharmacology & pharmacy (925) 925
survival (918) 918
medicine & public health (903) 903
breast neoplasms - pathology (887) 887
neoplasm metastasis (858) 858
bevacizumab (835) 835
antimetabolites, antineoplastic - therapeutic use (808) 808
drug therapy (805) 805
antineoplastic agents - therapeutic use (751) 751
prognosis (746) 746
combination (733) 733
surgery (733) 733
retrospective studies (711) 711
antineoplastic combined chemotherapy protocols - administration & dosage (708) 708
clinical trials (706) 706
radiotherapy (699) 699
hematology, oncology and palliative medicine (679) 679
carcinoma (678) 678
drug administration schedule (670) 670
analysis (659) 659
leucovorin (651) 651
1st-line treatment (646) 646
cisplatin (645) 645
survival rate (626) 626
adenocarcinoma - drug therapy (625) 625
antimetabolites, antineoplastic - adverse effects (621) 621
colorectal neoplasms - pathology (617) 617
health aspects (616) 616
phase-ii (614) 614
oncology, experimental (604) 604
irinotecan (592) 592
docetaxel (584) 584
antineoplastic agents (579) 579
stomach neoplasms - drug therapy (576) 576
antimetabolites, antineoplastic - administration & dosage (575) 575
gemcitabine (570) 570
tumors (565) 565
survival analysis (560) 560
antimitotic agents (547) 547
toxicity (547) 547
chemotherapy, adjuvant (541) 541
adenocarcinoma (539) 539
trastuzumab (539) 539
capecitabine - administration & dosage (526) 526
administration, oral (524) 524
cancer patients (524) 524
camptothecin - analogs & derivatives (511) 511
phase-iii trial (503) 503
phase-ii trial (501) 501
paclitaxel (498) 498
cancer research (480) 480
oral capecitabine (474) 474
chemoradiotherapy (472) 472
patients (472) 472
cancer therapies (470) 470
metastatic colorectal-cancer (468) 468
gastric cancer (460) 460
colorectal-cancer (456) 456
efficacy (453) 453
stomach cancer (449) 449
combined modality therapy (446) 446
follow-up studies (439) 439
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8261) 8261
Japanese (168) 168
German (101) 101
French (93) 93
Chinese (65) 65
Spanish (35) 35
Korean (26) 26
Italian (25) 25
Russian (23) 23
Polish (16) 16
Dutch (11) 11
Turkish (11) 11
Czech (10) 10
Hungarian (7) 7
Portuguese (4) 4
Danish (3) 3
Romanian (2) 2
Finnish (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dermatologic Therapy, ISSN 1396-0296, 05/2019, Volume 32, Issue 3, pp. e12853 - n/a
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2018, Volume 103, Issue 2, pp. 210 - 216
Journal Article
12/2010
Capecitabine is an oral chemotherapeutic agent converted to 5 flourouracil (5-FU). Neurotoxicity associated with the medication encompasses both central and... 
neurotoxicity | Capecitabine | cancer
Web Resource
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e384 - e386
Currently, treatment of small bowel adenocarcinoma (SBA) mirrors that of colorectal cancer (CRC). Recent genomic data have demonstrated SBA to be a genetically... 
CAPECITABINE | ONCOLOGY | PHASE-II
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 08/2018, Volume 18, Issue 4, pp. 289 - 297
We report the results from a phase I study of buparlisib, an oral pan-class I phosphotidyinositol-3-kinase inhibitor, combined with capecitabine in patients... 
Buparlisib | Breast cancer | Phase I | PI3K | Capecitabine | PLUS CAPECITABINE | TRASTUZUMAB | ONCOLOGY | PATHWAY | MUTATIONS | BKM120 | Capecitabine - administration & dosage | Breast Neoplasms - secondary | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | Adult | Female | Morpholines - adverse effects | Capecitabine - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Aminopyridines - toxicity | Drug Administration Schedule | Morpholines - administration & dosage | Capecitabine - toxicity | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - toxicity | Phosphatidylinositol 3-Kinases - genetics | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Antimetabolites, Antineoplastic - toxicity | Protein Kinase Inhibitors - toxicity | Morpholines - toxicity | Morpholines - pharmacokinetics | Mutation | Dosage and administration | Metastasis | Drug therapy, Combination | Drug therapy | Methods | Index Medicus
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 05/2016, Volume 14, Issue 1, pp. 125 - 125
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 1/2017, Volume 161, Issue 1, pp. 63 - 72
Journal Article
Journal Article
10/2011
A 59-year-old man with adenocarcinoma of stomach was prescribed capecitabine as adjuvant chemotherapy. After two cycles of therapy, patient developed... 
hyperpigmentation | Capecitabine | hand-foot syndrome
Web Resource
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article